Piscitelli Dominic sold $189K of ORIC

Piscitelli Dominic (Chief Financial Officer) sold 14,000 shares of Oric Pharmaceuticals, Inc. (ORIC) at $13.53 ($0.19M total) on 2026-10-20 under a Rule 10b5-1 trading plan.

Original reporting
SEC EDGAR · Piscitelli Dominic
Published Oct 21, 2026, 9:17 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Oct 21, 2026, 9:21 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefInsider activity
Primary signal
$ORIC
Neutral
high confidence
Mentioned
$ORIC
Relevance
3/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$ORICNeutralLow
01

Why it matters

Insider sales can influence sentiment, but 10b5-1 pre-arranged plans generally reduce the informational content versus discretionary selling.

02

Market read

Traders may note the insider sale for sentiment monitoring, but the filing does not introduce new fundamentals or catalysts.

03

What to watch

The article provides no context on total insider holdings, whether sales are part of a larger scheduled pattern, or whether the sale was driven by taxes or diversification needs.

Relevance 3/10Novelty 3/10Timing: filed after-hours on Oct. 21, transaction dated Oct. 20

Background

The article is a SEC Form 4 insider transaction disclosure for Oric Pharmaceuticals, Inc.

Company-level read

Ticker impact

$ORICNeutralHigh confidence
Context

Oric Pharmaceuticals CFO Dominic Piscitelli sold 14,000 shares in an open-market transaction under a pre-arranged 10b5-1 plan on Oct. 20.

Expected impact

Likely limited near-term impact, with any price reaction more dependent on broader market sentiment than on this Form 4.

Evidence & confidence

The filing is a Form 4 insider sale (code S) executed under a pre-arranged 10b5-1 plan, with no accompanying company-specific operational or guidance change disclosed in the text.

Market effects

Minimal, as this is an individual insider transaction with no disclosed sector-wide catalyst.

None indicated.

None indicated.

Counterpoint

Even with a 10b5-1 plan, repeated insider selling can still be interpreted by some traders as a mild negative signal about near-term outlook.

Key entities

  • Oric Pharmaceuticals, Inc.

    Company whose CFO Dominic Piscitelli executed an open-market sale under a pre-arranged 10b5-1 plan.

  • Dominic Piscitelli

    Chief Financial Officer who sold 14,000 shares at $13.5279 per share.

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

Related articles

$ORICMed

Wedbush reiterates Oric Pharmaceuticals stock rating on trial data

Wedbush reiterated an Outperform rating and $14.00 price target for ORIC Pharmaceuticals (ORIC) after its Q3 2026 earnings update. The stock is near its 52-week low at $7.52. InvestingPro values ORIC at $8.57. The company shared positive trial data for rinzimetostat in prostate cancer, with Phase 3 studies ongoing. BTIG and Stifel also issued Buy ratings with higher price targets.

$ORICMedAI 8/10

ORIC® Pharmaceuticals Reports Third Quarter 2026 Financial Results and Provides Operational and Rinzimetostat Program Updates

Oric Pharmaceuticals, Inc. (ORIC) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 ORIC ® Pharmaceuticals Reports Third Quarter 2026 Financial Results and Provides Operational and Rinzimetostat Program Updates Initiated Himalayas-1 global Phase 3 trial in patients with mCRPC previously treated with abiraterone, supported by a clinical trial collabo